CA2556794A1 - Use of beta-lapachone as a broad spectrum anti-cancer agent - Google Patents

Use of beta-lapachone as a broad spectrum anti-cancer agent Download PDF

Info

Publication number
CA2556794A1
CA2556794A1 CA002556794A CA2556794A CA2556794A1 CA 2556794 A1 CA2556794 A1 CA 2556794A1 CA 002556794 A CA002556794 A CA 002556794A CA 2556794 A CA2556794 A CA 2556794A CA 2556794 A1 CA2556794 A1 CA 2556794A1
Authority
CA
Canada
Prior art keywords
cancer
lapachone
pharmaceutically acceptable
acceptable salt
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002556794A
Other languages
English (en)
French (fr)
Inventor
Chiang J. Li
Youzhi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2556794A1 publication Critical patent/CA2556794A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
CA002556794A 2004-02-20 2005-02-18 Use of beta-lapachone as a broad spectrum anti-cancer agent Abandoned CA2556794A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54591604P 2004-02-20 2004-02-20
US60/545,916 2004-02-20
PCT/US2005/005647 WO2005082358A2 (en) 2004-02-20 2005-02-18 Use of beta-lapachone as a broad spectrum anti-cancer agent

Publications (1)

Publication Number Publication Date
CA2556794A1 true CA2556794A1 (en) 2005-09-09

Family

ID=34910740

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002556794A Abandoned CA2556794A1 (en) 2004-02-20 2005-02-18 Use of beta-lapachone as a broad spectrum anti-cancer agent

Country Status (4)

Country Link
EP (1) EP1722776A2 (https=)
JP (1) JP2007523192A (https=)
CA (1) CA2556794A1 (https=)
WO (1) WO2005082358A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
CN101119726B (zh) * 2005-02-16 2011-02-02 麦仁斯有限公司 用于治疗或预防涉及肥胖、糖尿病、代谢综合症、神经变性疾病和线粒体功能障碍疾病的疾病的药物组合物
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
JPWO2013153821A1 (ja) * 2012-04-12 2015-12-17 学校法人北里研究所 Ｐｄｋ４阻害剤及びその利用
JP7411875B2 (ja) * 2020-10-08 2024-01-12 株式会社 キュロム・バイオサイエンス ベータ－ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
AU2003254029A1 (en) * 2002-07-17 2004-02-02 Arqule, Inc. Activated checkpoint therapy and methods of use thereof
BR0316296A (pt) * 2002-11-18 2005-12-13 Arqule Inc Compostos lapacone e seus métodos de uso
WO2004050033A2 (en) * 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers

Also Published As

Publication number Publication date
EP1722776A2 (en) 2006-11-22
JP2007523192A (ja) 2007-08-16
WO2005082358A2 (en) 2005-09-09
WO2005082358A3 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
Wei et al. Cordycepin inhibits drug-resistance non-small cell lung cancer progression by activating AMPK signaling pathway
US7361691B2 (en) Method of treating cancers using β-lapachone or analogs or derivatives thereof
US6214821B1 (en) Methods and composition for the inhibition of cancer cells
US20190134044A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
Ku et al. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
Behera et al. Implication of methylselenocysteine in combination chemotherapy with gemcitabine for improved anticancer efficacy
CA2556794A1 (en) Use of beta-lapachone as a broad spectrum anti-cancer agent
WO2007132220A1 (en) Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
EP2033640A2 (en) Beta-lapachone for the treatment of lung cancer
CA2556789A1 (en) Use of beta-lapachone for treating hematologic tumors
US20050222246A1 (en) Beta-lapachone is a broad spectrum anti-cancer agent
US20050192360A1 (en) Method of treatment of pancreatic cancer
Yu et al. Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells
EP2033638A2 (en) Beta-lapachone for the treatment of pancreatic cancer
Parekh et al. Circumvention of adriamycin resistance: effect of 2-methyl-1, 4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells
US20050197406A1 (en) Method of treatment of lung cancer
US20050197405A1 (en) Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
Hsu et al. 2-(3-Fluorophenyl)-6-methoxyl-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (YJC-1) induces mitotic phase arrest in A549 cells
US20050192361A1 (en) Method of treatment of colon cancer
EP2033639A2 (en) Beta-lapachone for the treatment of colon cancer
CA2556759A1 (en) Beta-lapachone and s-phase drug combinations for cancer treatment
US20250144054A1 (en) Small molecule stat3 inhibitor for treating triple negative breast cancer
US20050192247A1 (en) Method of treating cancers
RU2784809C2 (ru) Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения
KR101046630B1 (ko) Ｓ-아데노실메티오닌을 유효성분으로 함유하는 암세포 특이적인 항암보조용 약제학적 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20091229